Switching to guselkumab for psoriasis treatment was associated with the greatest rate of treatment persistence when compared with other therapies.

More patients with oligoarticular psoriatic arthritis (PsA) saw symptoms largely disappear when apremilast (Otezla) was started early in the disease course compared with placebo, a randomized trial ...

Please provide your email address to receive an email when new articles are posted on . Apremilast led to better clinical outcomes in early oligoarticular PsA vs. placebo at 16 weeks. Safety was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At week 16, 55.9% of the risankizumab group and 5.1% of ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Apremilast (Otezla), an oral drug approved for adult psoriasis, appears to reduce psoriasis severity in some children with moderate to severe psoriasis not controlled by topical therapy, according to ...

Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...

Learn everything you need to know about Apremilast-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

As per IQVIATM sales data covering the 12-month period up to August 2023, the market for Otezla® tablets in these dosage forms achieved annual sales of around $3.7 billion. Mumbai: Glenmark ...

Review the side-effects of Apremilast as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

A 24-week, randomized, placebo-controlled phase III trial (PALACE 1) has found that apremilast (an oral phosphodiesterase 4 inhibitor) is an effective treatment for patients with active psoriatic ...

Celgene (CELG +0.00%) has good news -- and it has bad news. The company announced phase 3 results for apremilast in treating psoriasis at the American Academy of Dermatology meeting this weekend in ...